Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacyclics (PCYC) -- Ignore unavailable to you. Want to Upgrade?

To: Curtis Frazier who wrote (322)	5/13/1998 12:06:00 PM
From: George Holt	Read Replies (2) \| Respond to of 717

MM saw fit to move the price down. There was no selling pressure previous. Picked up Jun 35 calls at 1 3/16. Following is February News Item; Sorry if it was previously posted: Smart drugs battle brain cancer United Press International - February 14, 1998 18:45 By ED SUSMAN PHILADELPHIA, Feb. 14 (UPI) - Researchers say they have successfully sent molecules to locate and destroy cancer cells in patients whose brain tumors have spread, more than doubling their expected live span. At the American Association for the Advancement of Science meeting in Philadelphia, scientists say patients treated with these designed molecules called texaphyrins (''TEX-uh-frinz'') have survived more than a year, while currently treated patients die within four months after the cancer spreads. Jonathan Sessler, professor of chemistry at the University of Texas at Austin, has treated 24 patients with texaphrins - larger than normal copies of porphyrins, natural pigment molecules. The texaphyrins are taken up by cancer cells in a 10 to 1 ratio to normal cells. Sessler says the texaphyrins' size allows them to carry heavy metals such as gadolinium to cancer sites which can be imaged through magnetic resonance tehnology. That gives radiologists a chance to find smaller tumors and to pinpoint radiation doses on those sites, killing tumor cells but not normal brain tissue. Sessler says a clinical trial using the same technique is beginning for people suffering recurrent breast cancer. About 20 patients are enrolled in the breast cancer trial. Sessler says texaphyrins, manufacturered by Sessler's Pharmacyclics, Inc., company in Sunnyvale, Calif., will be included in additional National Cancer institute trials in 1998. George